CRCT News
A novel imaging approach for single-cell, real-time analysis of oncolytic virus replication and efficacy in cancer cells
Oncolytic viruses infect and replicate in cancer cells to induce cell death. As such, they are promising new therapies against cancer. This study describes for the first time the antitumor activity of SG33, a veterinary vaccine strain derived from the Myxoma virus....
Normalization of protein secretion in tumour microenvironment inhibits metastasis development in pancreatic cancer
Fibroblasts present in pancreatic tumours produce large amounts of proteins, which promote the proliferation of cancer cells, as well as their ability to metastasize. We have shown that these fibroblasts can be targeted using a somatostatin analogue SOM230, a molecule...
Protocol to select antibodies that deplete their antigen inside the cells.
It is important to be able to identify and validate new therapeutic strategies for proteins that are not currently targeted by inhibitors in cancers. Therapeutic antibodies are molecules of choice for the standard treatment of many forms of cancer. Their application...
Identification of therapeutic targets and drug repurposing against Covid19 based on proteins, diseases, drugs, and symptoms network analysis
Network medicine aims at using networks to uncover patterns in diseases and use them to understand their biology and propose new drugs. Since the appearance of Covid19, the disease provoked by the SARS-Cov-2 virus, the research community all around the globe has been...
Genetic polymorphisms involved in trabectedin-related liver toxicity.
Trabectedin is a cytotoxic drug used for the treatment of advanced soft tissue sarcoma. One of the most frequent side effects is hepatotoxicity, which occurs in nearly 40% of patients. In this pharmacogenetic study, we aimed to identify genetic polymorphisms that...
Cancer: a key mechanism of resistance to immunotherapy identified
An international team [1], led by Dr Ludovic Martinet (Inserm researcher) and Pr Hervé Avet-Loiseau from the Toulouse Cancer Research Centre (CRCT / Inserm, University of Toulouse III - Paul Sabatier, CNRS), has just published a study in the journal Immunity which...